Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 89

Sort by

Sort Order Select

Journal Articles

Clinical efficacy of allogeneic hematopoietic stem cell transplantation in infant acute leukemia

Ruijuan Sun, Min Xiong, Zhijie Wei, Deyan Liu, Jian-Ping Zhang, Jiarui Zhou, Xingyu Cao, Yue Lu, Yanli Zhao, Peihua Lu

Blood (2025) 146 (Supplement 1): 6053.

https://doi.org/10.1182/blood-2025-6053

Published: 2025

Journal Articles

Safety and efficacy of blinatumomab for EBV viremia and PTLD following allogeneic hematopoietic stem cell transplantation

Yunchao Su, Song Xue, Wei Ma, Fan Yang, Yaya Qi, Lihua Wang, Fei Pan, Jicong Liu, Yuefeng Tian, Fangfang Zhang, Peihua Lu, Xingyu Cao

Blood (2025) 146 (Supplement 1): 6061.

https://doi.org/10.1182/blood-2025-6061

Published: 2025

Journal Articles

Single-center retrospective analysis of maribavir in the treatment of refractory and drug-intolerant cytomegalovirus viremia and cytomegalovirus disease after allogeneic hematopoietic stem cell transplantation

Wei Ma, Xingyu Cao, Jiarui Zhou, Jian-Ping Zhang, Yue Lu, Ruijuan Sun, Zhijie Wei, Deyan Liu, Yanli Zhao, Min Xiong, Peihua Lu

Blood (2025) 146 (Supplement 1): 6059.

https://doi.org/10.1182/blood-2025-6059

Published: 2025

Journal Articles

Safety and efficacy of IL-6 knockdown anti-CD19 CAR-T cells (ssCART-19) in the treatment of primary/secondary central nervous system lymphoma

Blood (2025) 146 (Supplement 1): 927.

https://doi.org/10.1182/blood-2025-927

Published: 2025

Journal Articles

Efficacy and safety analysis of letermovir for the prevention of CMV infection after haploidentical hematopoietic stem cell transplantation in children with acute leukemia

Huili Zhu, Zhijie Wei, Peihua Lu

Blood (2025) 146 (Supplement 1): 2440.

https://doi.org/10.1182/blood-2025-2440

Published: 2025

Journal Articles

CTD402, allogeneic anti-CD7 CAR t-cell, in relapsed or refractory (R/R) t-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL) - report of clinical outcomes at the recommended phase 2 dose (RP2D)

Blood (2025) 146 (Supplement 1): 1042.

https://doi.org/10.1182/blood-2025-1042

Published: 2025

Journal Articles

CD7-targeted CAR-T cell therapy showed a high efficacy for 30 patients with relapsed or refractory central nervous system T-cell lymphoblastic leukemia/lymphoma

Junfang Yang, Xian Zhang, Jingjing Li, Liyuan Qiu, Peihua Lu

Blood (2025) 146 (Supplement 1): 1039.

https://doi.org/10.1182/blood-2025-1039

Published: 2025

Journal Articles

CD7 CAR-T cell therapy based on “Natural Selection” for the treatment of Relapsed or Refractory CD7-positive Hematologic Malignancies: A large cohort study

Xian Zhang, Junfang Yang, Gailing Zhang, Min Zhang, Na Kuang, Shuyu Qiang, Peihua Lu

Blood (2025) 146 (Supplement 1): 2540.

https://doi.org/10.1182/blood-2025-2540

Published: 2025

Journal Articles

CD3⁺cell dose is an independent risk factor for grade II–IV aGVHD following cord blood transplantation in children with aplastic anemia

Jian-Ping Zhang, Li Nannan, Min Xiong, Jing Long, Xingyu Cao, Yue Lu, Zhijie Wei, Deyan Liu, Ruijuan Sun, Jiarui Zhou, Yanli Zhao, Jun-bao He, Peihua Lu

Blood (2025) 146 (Supplement 1): 7752.

https://doi.org/10.1182/blood-2025-7752

Published: 2025

Journal Articles

Safety and efficacy of CD19/CD22/CD20 multi-targeted CAR-T therapy in patients with refractory/relapsed B-cell non-Hodgkin lymphoma

Xiyang Liu, Liqing Kang, Hongfei Gu, Wei Zhang, Hongjia Zhu, Xue Lu, Huan Zhou, Xingyue Wang, Nan Xu, Xiaoyan Lou, Minghao Li, Wei Wang, Zhou Yu, Jingwen Tan, Jing Ye, Israth Jahan Tuhin, Lei Yu, Peihua Lu

Blood (2025) 146 (Supplement 1): 3713.

https://doi.org/10.1182/blood-2025-3713

Published: 2025

Journal Articles

Glofitamab use may significantly reduce the efficacy of CAR-T therapy in R/R DLBCL patients

Xiyang Liu, Hongjia Zhu, Wei Zhang, Liqing Kang, Hongfei Gu, Xue Lu, Huan Zhou, Xingyue Wang, Nan Xu, Xiaoyan Lou, Minghao Li, Wei Wang, Zhou Yu, Jingwen Tan, Jing Ye, Israth Jahan Tuhin, Peihua Lu, Lei Yu

Blood (2025) 146 (Supplement 1): 2382.

https://doi.org/10.1182/blood-2025-2382

Published: 2025

Journal Articles

Efficacy of early single low dose of rituximab in prophylaxis of EBV reactivation and EBV related post-transplant lymphoproliferative disorder after allogeneic hematopoietic cell transplantation

Fang Liu, Yecheng Li, Gele Tong, Lina Feng, Jing Wu, Yu Sun, Min Chen, Peihua Lu

Blood (2025) 146 (Supplement 1): 7803.

https://doi.org/10.1182/blood-2025-7803

Published: 2025

Journal Articles

Allo-HSCT mitigates the prognostic differences between bZIP and non-bZIP CEBPA mutations in AML: A long-term follow-up study of lu daopei hospital

Yanli Zhao, Yue Lu, Deyan Liu, Jian-Ping Zhang, Zhijie Wei, Xingyu Cao, Ruijuan Sun, Min Xiong, Jiarui Zhou, Jing Long, Tong Wang, Hongxing Liu, Peihua Lu

Blood (2025) 146 (Supplement 1): 6049.

https://doi.org/10.1182/blood-2025-6049

Published: 2025

Journal Articles

A novel loop-structured CD19/CD22 dual-targeting CAR-T therapy for patients with refractory/relapsed B-cell non-Hodgkin lymphoma

Wei Zhang, Nan Xu, Hongfei Gu, Xiyang Liu, Liqing Kang, Hongjia Zhu, Xingyue Wang, Xue Lu, Huan Zhou, Wei Wang, Zhou Yu, Jingwen Tan, Jing Ye, Israth Jahan Tuhin, Xiaoyan Lou, Minghao Li, Lei Yu, Peihua Lu

Blood (2025) 146 (Supplement 1): 4152.

https://doi.org/10.1182/blood-2025-4152

Published: 2025

Journal Articles

Impact of germline and somatic TP53 mutations on allogeneic HSCT outcomes in hematologic malignancies

Xingyu Cao, Yang Zhang, Lili Yuan, Yue Lu, Jian-Ping Zhang, Zhijie Wei, Deyan Liu, Min Xiong, Yanli Zhao, Jiarui Zhou, Ruijuan Sun, Mengyuan Niu, Fangmin Pan, Jing Long, Peihua Lu

Blood (2025) 146 (Supplement 1): 7786.

https://doi.org/10.1182/blood-2025-7786

Published: 2025

Journal Articles

Allogeneic hematopoietic stem cell transplantation in sil::TAL1-positive T-ALL: Prognostic impact of pre-transplant remission and molecular status

Xiao-hong Liu, Jing Long, Jiarui Zhou, Min Xiong, Xingyu Cao, Jian-Ping Zhang, Yue Lu, Zhijie Wei, Yanli Zhao, Ruijuan Sun, Fangmin Pan, Peihua Lu, Deyan Liu

Blood (2025) 146 (Supplement 1): 2502.

https://doi.org/10.1182/blood-2025-2502

Published: 2025

Journal Articles

Optimizing letermovir timing: Day +5 to +8 post haplo-HSCT minimizes EBV dnaemia without compromising CMV prophylaxis

Xingyu Cao, Yue Lu, Jian-Ping Zhang, Zhijie Wei, Deyan Liu, Min Xiong, Yanli Zhao, Jiarui Zhou, Ruijuan Sun, Mengyuan Niu, Fangmin Pan, Jing Long, Peihua Lu

Blood (2025) 146 (Supplement 1): 2500.

https://doi.org/10.1182/blood-2025-2500

Published: 2025

Journal Articles

The impact of HLA loss of heterozygosity on outcome after haploidentical hematopoietic stem cell transplantation in hematological malignancies

Xingyu Cao, Jian-ling Wang, Yanli Zhao, Min Xiong, Yue Lu, Ruijuan Sun, Jian-Ping Zhang, Deyan Liu, Jiarui Zhou, Zhijie Wei, Peihua Lu

Blood (2025) 146 (Supplement 1): 2498.

https://doi.org/10.1182/blood-2025-2498

Published: 2025

Journal Articles

No reduction in gvhd risk for aplastic anemia patients to combined third-party unrelated cord blood in haploidentical hematopoietic stem cells transplantation

Wei Zhao, Xingyu Cao, Yue Lu, Jian-Ping Zhang, Zhijie Wei, Deyan Liu, Min Xiong, Jiarui Zhou, Ruijuan Sun, Jing Long, Peihua Lu, Yanli Zhao

Blood (2025) 146 (Supplement 1): 2495.

https://doi.org/10.1182/blood-2025-2495

Published: 2025

Journal Articles

Multi-hit TP53 mutation is an independent adverse prognostic factor in allogeneic hematopoietic stem cell transplantation for acute leukemia and myelodysplastic syndromes

Yanli Zhao, Yue Lu, Deyan Liu, Jian-Ping Zhang, Zhijie Wei, Xingyu Cao, Ruijuan Sun, Jiarui Zhou, Min Xiong, Jing Long, Tong Wang, Peihua Lu

Blood (2025) 146 (Supplement 1): 2493.

https://doi.org/10.1182/blood-2025-2493

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Clinical efficacy of allogeneic hematopoietic stem cell transplantation in infant acute leukemia

Safety and efficacy of blinatumomab for EBV viremia and PTLD following allogeneic hematopoietic stem cell transplantation

Single-center retrospective analysis of maribavir in the treatment of refractory and drug-intolerant cytomegalovirus viremia and cytomegalovirus disease after allogeneic hematopoietic stem cell transplantation

Safety and efficacy of IL-6 knockdown anti-CD19 CAR-T cells (ssCART-19) in the treatment of primary/secondary central nervous system lymphoma

Efficacy and safety analysis of letermovir for the prevention of CMV infection after haploidentical hematopoietic stem cell transplantation in children with acute leukemia

CTD402, allogeneic anti-CD7 CAR t-cell, in relapsed or refractory (R/R) t-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL) - report of clinical outcomes at the recommended phase 2 dose (RP2D)

CD7-targeted CAR-T cell therapy showed a high efficacy for 30 patients with relapsed or refractory central nervous system T-cell lymphoblastic leukemia/lymphoma

CD7 CAR-T cell therapy based on “Natural Selection” for the treatment of Relapsed or Refractory CD7-positive Hematologic Malignancies: A large cohort study

CD3⁺cell dose is an independent risk factor for grade II–IV aGVHD following cord blood transplantation in children with aplastic anemia

Safety and efficacy of CD19/CD22/CD20 multi-targeted CAR-T therapy in patients with refractory/relapsed B-cell non-Hodgkin lymphoma

Glofitamab use may significantly reduce the efficacy of CAR-T therapy in R/R DLBCL patients

Efficacy of early single low dose of rituximab in prophylaxis of EBV reactivation and EBV related post-transplant lymphoproliferative disorder after allogeneic hematopoietic cell transplantation

Allo-HSCT mitigates the prognostic differences between bZIP and non-bZIP CEBPA mutations in AML: A long-term follow-up study of lu daopei hospital

A novel loop-structured CD19/CD22 dual-targeting CAR-T therapy for patients with refractory/relapsed B-cell non-Hodgkin lymphoma

Impact of germline and somatic TP53 mutations on allogeneic HSCT outcomes in hematologic malignancies

Allogeneic hematopoietic stem cell transplantation in sil::TAL1-positive T-ALL: Prognostic impact of pre-transplant remission and molecular status

Optimizing letermovir timing: Day +5 to +8 post haplo-HSCT minimizes EBV dnaemia without compromising CMV prophylaxis

The impact of HLA loss of heterozygosity on outcome after haploidentical hematopoietic stem cell transplantation in hematological malignancies

No reduction in gvhd risk for aplastic anemia patients to combined third-party unrelated cord blood in haploidentical hematopoietic stem cells transplantation

Multi-hit TP53 mutation is an independent adverse prognostic factor in allogeneic hematopoietic stem cell transplantation for acute leukemia and myelodysplastic syndromes

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only